Failure of rivaroxaban to prevent thrombosis in four patients with anti-phospholipid syndrome

Rheumatology (United Kingdom)

Volumn 56, Issue 8, 2017, Pages 1433-1434

  Dufrost, Virginie ^a   Risse, Jessie ^a,b   Kirchner, Stéphane ^c   Zuily, Stéphane ^a,b   Wahl, Denis ^a,b  

^a UNIVERSITY HOSPITAL OF NANCY   (France)

^b UNIVERSITÉ DE LORRAINE   (France)

^c Pathology Center Emile Gallé   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ACENOCOUMAROL; ACETYLSALICYLIC ACID; LOW MOLECULAR WEIGHT HEPARIN; RIVAROXABAN; THROMBIN; ANTICOAGULANT AGENT;

ADULT; ANTICOAGULANT THERAPY; ANTIPHOSPHOLIPID SYNDROME; ARTERY THROMBOSIS; CASE REPORT; CLINICAL ARTICLE; DEEP VEIN THROMBOSIS; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; DYSPNEA; FEMALE; HIGH RISK PATIENT; HUMAN; LABORATORY TEST; LETTER; LUNG EMBOLISM; MALE; MIDDLE AGED; PATIENT PREFERENCE; PRIORITY JOURNAL; SAPHENOUS VEIN; SKIN DEFECT; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOCYTOPENIA; THROMBOSIS PREVENTION; YOUNG ADULT; THROMBOSIS; TREATMENT FAILURE;

ADULT; ANTICOAGULANTS; ANTIPHOSPHOLIPID SYNDROME; FEMALE; HUMANS; MALE; MIDDLE AGED; RIVAROXABAN; THROMBOSIS; TREATMENT FAILURE; YOUNG ADULT;

EID: 85028322188     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kex086     Document Type: Letter

References (8)

1. Miyakis S, Lockshin MD, Atsumi T et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006;4:295-306.
2. EINSTEIN Investigators, Bauersachs R, Berkowitz SD et al. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 2010;363:2499-510.
3. Son M, Wypasek E, Celinska-LowenhoffM, Undas A. The use of rivaroxaban in patients with antiphospholipid syndrome: a series of 12 cases. Thromb Res 2015;135:1035-6.
4. Betancur JF, Bonilla-Abad-ia F, Hormaza AA et al. Direct oral anticoagulants in antiphospholipid syndrome: a real life case series. Lupus 2016;25:658-62.
5. Pengo V, Ruffatti A, Legnani C et al. Incidence of a first thromboembolic event in asymptomatic carriers of highrisk antiphospholipid antibody profile: a multicenter prospective study. Blood 2011;118:4714-8.
6. Cohen H, Hunt BJ, Efthymiou M et al. Rivaroxaban versus warfarin to treat patients with thrombotic antiphospholipid syndrome, with or without systemic lupus erythematosus (RAPS): a randomised, controlled, openlabel, phase 2/3, non-inferiority trial. Lancet Haematol 2016;3:e426-36.
7. Dufrost V, Risse J, Zuily S, Wahl D. Direct oral anticoagulants use in antiphospholipid syndrome: are these drugs an effective and safe alternative to warfarin? A systematic review of the literature. Curr Rheumatol Rep 2016;18:74.
8. Pengo V, Banzato A, Bison E et al. Efficacy and safety of rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome: Rationale and design of the Trial on Rivaroxaban in AntiPhospholipid Syndrome (TRAPS) trial. Lupus 2016;25:301-6.